NRG1 gene fusion is a rare and clinically distinct molecular alteration found in a small subset of non-small cell lung cancer (NSCLC) patients. Its identification in the setting of advanced or metastatic disease shapes the first-line treatment approach.
NRG1 gene fusions are rare, estimated to occur in fewer than 1% of patients diagnosed with NSCLC. Their presence carries specific therapeutic significance that informs treatment selection in the advanced and metastatic setting.
First-line management involves systemic therapy — which may include chemotherapy, with or without immunotherapy. The full regimen options, selection criteria, and individualized sequencing are detailed in the complete protocol.
NRG1 gene fusions are rare and estimated to occur in <1% of patients diagnosed with NSCLC.
The presence of an NRG1 gene fusion is associated with responsiveness to a HER2/HER3 bispecific antibody.
The Panel recommends systemic therapy regimens (such as chemotherapy with or without immunotherapy) listed in the Principles of Systemic Therapy for Advanced or Metastatic Disease (NSCL-K) in the NCCN Guidelines for NSCLC [at www.NCCN.org] for the first-line treatment of advanced or metastatic NSCLC with an NRG1 gene fusion.